The on-label, prospective, multi-center study showed meaningful relief using DTM SCS endurance therapy, a modified, lower-energy variation of Medtronic’s Differential Target Multiplexed (DTM) SCS therapy for chronic overall, back or leg pain.
According to a news release, at three months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS). They also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.
The three-month results are consistent with data from a prior feasibility study, Medtronic said. Additional data included 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having minimal or moderate disability at three months compared to 16% at baseline. Additionally, 75% of patients were “very satisfied” or “somewhat satisfied” with their therapy at three months.
DTM SCS endurance therapy enables between 5.5 and 7.5 years of device longevity when programmed on the Vanta recharge-free neurostimulator, according to modeling based on the three-month data. DTM SCS endurance therapy programmed on the Intellis rechargeable neurostimulator allows either rapid recharge (five minutes per day) or recharges of approximately one hour every 12 days.
Patients enrolled in the trial will have additional follow-up assessments at six months and at 12 months, Medtronic said. Three-month findings were presented at the 25th Annual North American Neuromodulation Society (NANS) Annual Meeting this week.
“Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalize care for our patients,” Medtronic VP and GM of Pain Therapies within the Neuromodulation Business Charlie Covert said in the release. “For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity.”